64 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Apr 24
Regulation FD Disclosure
4:30pm
-baseline assessment. All objective responses were confirmed per RECIST v 1.1. Data include patients on all schedules of azenosertib plus chemotherapy. Liu
8-K
EX-99.2
m7dbgm p6
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.1
y82x0yibfflgd
13 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
nbc51dvkeep4d38ame
9 Aug 23
Regulation FD Disclosure
4:15pm
8-K
EX-99.3
m8xu98d1e ohi649
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.2
jp6q45ol
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.2
i2r3fhsqy r3sr
5 Jun 23
Regulation FD Disclosure
2:24pm
8-K
EX-99.1
rct9st60vglx
5 Jun 23
Regulation FD Disclosure
2:24pm
PRE 14A
m3l0c12xw
18 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.2
5wev 2ax5z
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
8-K
EX-99.2
es4ey
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am